Search results for "cost-benefit"

showing 10 items of 153 documents

Effectiveness of a physical therapeutic exercise programme for caregivers of dependent patients: a pragmatic randomised controlled trial from Spanish…

2020

Producción Científica

Health Toxicology and MutagenesisCalidad de vidaCost-Benefit Analysislcsh:Medicinefemale caregivers3213.11 Fisioterapialaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicineRandomized controlled triallawSalud pública030212 general & internal medicineFisioterapiaFamily caregiverspublic healthCuidadores:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Exercise TherapyTreatment OutcomeCaregiversAnxietyFemalePublic Healthmedicine.symptom:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities::Exercise Therapy [Medical Subject Headings]Developed countryQuality of lifemedicine.medical_specialty:Health Care::Health Care Facilities Manpower and Services::Health Personnel::Caregivers [Medical Subject Headings]Exercise therapyArticle03 medical and health sciencesprimary careQuality of life (healthcare):Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings]Atención primaria de salud32 Ciencias MédicasmedicineHumansWomen:Humanities::Humanities::Philosophy::Life::Quality of Life [Medical Subject Headings]physiotherapyPrimary care (Medicine):Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]therapeutic exercisePrimary Health Carebusiness.industryPublic healthlcsh:RPublic Health Environmental and Occupational HealthMental healthClinical trial:Check Tags::Female [Medical Subject Headings]quality of lifeSpainDependenciaPhysical therapybusinessCuidador familiarPhysical therapy030217 neurology & neurosurgery
researchProduct

Screening Investments to Reduce the Risk of Hydrologic Failures in the Headwork System Supplying Apulia (Italy) – Role of Economic Evaluation and Ope…

2014

The paper introduces and applies a methodology to screen investments aimed at reducing water supply risks due to hydrologic failures in headwork systems for municipal use, based on the principles of cost-benefit analysis. As risk includes both the probability of a failure and its effect, the methodology combines a simulation module of the system, fed by a stochastic hydrologic input to reproduce the probability distribution of the failures, with a metric for supply failure damage provided by the price – demand relationship for municipal water. Benefits are assessed as the averted damage compared to a base case without investments. This approach is then combined with the classic discounted c…

HydrologyDroughtCost–benefit analysisbusiness.industrySettore ICAR/02 - Costruzioni Idrauliche E Marittime E IdrologiaWater supplyStochastic hydrologyRankingEconomic indicatorDemand curveWater transferEconomic evaluationCost-benefit analysiEconomicsProduction (economics)Metric (unit)business.Water resources systemWater Science and TechnologyCivil and Structural EngineeringWater Resources Management
researchProduct

Long-term resource utilisation and associated costs of exercise during (neo)adjuvant oncological treatment: the Phys-Can project

2022

Background Exercise during oncological treatment is beneficial to patient health and can counteract the side effects of treatment. Knowledge of the societal costs associated with an exercise intervention, however, is limited. The aims of the present study were to evaluate the long-term resource utilisation and societal costs of an exercise intervention conducted during (neo)adjuvant oncological treatment in a randomised control trial (RCT) versus usual care (UC), and to compare high-intensity (HI) versus low-to-moderate intensity (LMI) exercise in the RCT. Methods We used data from the Physical Training and Cancer (Phys-Can) project. In the RCT, 577 participants were randomised to HI or to …

Hälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomiCancer; exercise; health care costs; sick leave; costs; cost analysisCost-Benefit Analysiscostssick leavecost analysisNeoplasmshealth care costsHumansRadiology Nuclear Medicine and imagingSjukgymnastikExercisePhysiotherapyPhysical Therapy ModalitiesCancerCancer och onkologiexerciseResistance TrainingHematologyGeneral MedicineHealth Care Service and Management Health Policy and Services and Health EconomyHealth ServicesVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762OncologyCancer and OncologyQuality of Life
researchProduct

Economic and environmental sustainability of submerged anaerobic MBR-based (AnMBR-based) technology as compared to aerobic-based technologies for mod…

2015

[EN] The objective of this study was to assess the economic and environmental sustainability of submerged anaerobic membrane bioreactors (AnMBRs) in comparison with aerobic-based technologies for moderate-/high-loaded urban wastewater (UWW) treatment. To this aim, a combined approach of steady-state performance modelling, life cycle analysis (LCA) and life cycle costing (LCC) was used, in which AnMBR (coupled with an aerobic-based post-treatment) was compared to aerobic membrane bioreactor (AeMBR) and conventional activated sludge (CAS). AnMBR with CAS-based post-treatment for nutrient removal was identified as a sustainable option for moderate-/high-loaded UWW treatment: low energy consump…

INGENIERIA HIDRAULICAEngineeringEnvironmental EngineeringCost-Benefit Analysis0208 environmental biotechnologySewageEnvironmental pollution02 engineering and technologyWastewater010501 environmental sciencesManagement Monitoring Policy and LawMembrane bioreactorGlobal Warming01 natural sciencesWater PurificationBioreactorsBioreactorAnaerobiosisWaste Management and DisposalTECNOLOGIA DEL MEDIO AMBIENTE0105 earth and related environmental sciencesLife cycle costing (LCC)SewageLife cycle analysis (LCA)Steadystate performance modellingbusiness.industryUrbanizationSubmerged anaerobic MBR (AnMBR)Environmental engineeringMembranes ArtificialGeneral MedicineModels TheoreticalGlobal warming potential (GWP)Aerobiosis020801 environmental engineeringActivated sludgeWastewaterSewage treatmentEnvironmental PollutionbusinessAnaerobic exerciseJournal of Environmental Management
researchProduct

New development opportunities for the craft brewing segment: the case study of a micro-malthouse

2017

In Italy in the past few years, the number of small breweries penetrating the craft beer sector has grown exponentially. Craft producers intend to give a strong added value and a local character to their production in different ways. One of these is the use of malt derived from small batches of local cereals and pseudo cereals. The aim of this study is the assessment of investment profitability, through a cost-benefit analysis (CBA), for a compact and a modular micro-malting plant in Sicily (Southern Italy). The CBA for a micro-malthouse was carried out considering both installation and operating costs. Net present value (NPV), discounted benefit-cost ratio (DBCR) and internal rate of retur…

Internal areasInformation Systems and Managementinternal areas.Management Science and Operations ResearchNet present valueCBA; Cereal processing; Cost-benefit analysis; Internal areas; Malting; Malting plant; SicilyCraftAgricultural scienceSettore AGR/01 - Economia Ed Estimo RuraleAdded valueProduction (economics)maltingBusiness and International ManagementSicilybusiness.industryCost-benefit analysisInternal rate of returnSettore AGR/15 - Scienze E Tecnologie AlimentariInvestment (macroeconomics)malting plantcereal processingcost–benefit analysiBrewingProfitability indexbusinessCBA
researchProduct

Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis

2012

BackgroundCost-Effectiveness Analysis (CEA) has been promoted as an important research methodology for determining the efficiency of healthcare technology and guiding medical decision-making. Our aim was to characterize the collaborative patterns of CEA conducted over the past two decades in Spain.Methods and findingsA systematic analysis was carried out with the information obtained through an updated comprehensive literature review and from reports of health technology assessment agencies. We identified CEAs with outcomes expressed as a time-based summary measure of population health (e.g. quality-adjusted life-years or disability-adjusted life-years), conducted in Spain and published bet…

Knowledge managementNon-Clinical MedicineCost effectivenessScience PolicyEconomicsPolitical ScienceCost-Benefit AnalysisSciencePublic PolicyBibliometricsTechnology assessmentSocial and Behavioral SciencesInvestigacióHealth EconomicsSociologyMedicineCooperative BehaviorHealth Systems StrengtheningMultidisciplinaryHealth economicsHealth Care PolicyCost–benefit analysisbusiness.industryQHealth services researchRHealth technologyCost-effectiveness analysisResearch AssessmentAuthorshipSocial NetworksBibliometricsMedicinebusinessResearch Article
researchProduct

Efficacy and cost-effectiveness of the UltraCision harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial.

2004

Thyroid surgery technique has undergone very few changes in the last century. The UltraCision harmonic scalpel (UHS) (Smithfield, RI) has been widely used in laparoscopic surgery and is documented to be safe and fast for cutting and coagulating tissue. We studied whether the use of the UHS could have advantages in thyroid surgery in terms of operative time, length of hospitalization, morbidity, and general costs.Our study was a prospective randomized trial of thyroidectomies and lobectomies performed for benign thyroid diseases in an endocrine surgery unit between February 2001 and July 2002. Patients were randomized in two groups: group A (n=100) underwent thyroidectomy using UHS and group…

Laparoscopic surgeryAdultMalemedicine.medical_specialtyAdolescentCost effectivenessmedicine.medical_treatmentCost-Benefit Analysislaw.inventionRandomized controlled triallawmedicineHarmonic scalpelHumansProspective StudiesProspective cohort studyAgedUltrasonographyAged 80 and overbusiness.industryThyroidectomyMiddle AgedThyroid DiseasesSurgeryClinical trialEndocrine surgeryTreatment OutcomeThyroidectomySurgeryFemalebusinessJournal of laparoendoscopicadvanced surgical techniques. Part A
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?

2016

In Italy, the Italian Pharmaceutical Agency (AIFA) criteria used F3–F4 fibrosis stages as the threshold to prioritise the treatment with interferon (IFN)-free regimens, while in genotype 1 chronic hepatitis C (G1 CHC) patients with fibrosis of liver stage 2, an approach with pegylated interferon (PEG-IFN)-based triple therapy with simeprevir was suggested. The key clinical question is whether, in an era of financial constraints, the application of a universal IFN-free strategy in naive G1 CHC patients is feasible within a short time horizon. The aim of this study is to perform an economic analysis to estimate the cost-utility of the early innovative therapy in Italy for managing hepatitis C…

Liver CirrhosisSimeprevirmedicine.medical_specialtyCost-Benefit AnalysisPopulationAntiviral Agents03 medical and health sciencesIndirect costs0302 clinical medicineAntiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome; Pharmacology (medical)SimeprevirRibavirinmedicineHumansPharmacology (medical)030212 general & internal medicineChronicIntensive care medicineeducationReimbursementeducation.field_of_studyCost–benefit analysisbusiness.industryHealth services researchGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CMarkov ChainsQuality-adjusted life yearTreatment OutcomeItalyDisease Progression030211 gastroenterology & hepatologyInterferonsQuality-Adjusted Life YearsbusinessMonte Carlo MethodClinical Drug Investigation
researchProduct

Why do I treat my patients with mild hepatitis C?

2015

The major advances achieved in the treatment of HCV by the development of new direct-acting antiviral agents (DAAs) allow treatment of almost the entire spectrum of patients with chornic infection. As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. Hence, treatment of patients with milder liver disease is often deferred. This could ultimately result in an increased burden of advanced liver disease and in increased long-term costs of management. Moreover, studies performed during the 'interferon era' and the early data on interferon-free regimens show that patients without severe fibro…

Liver Cirrhosismedicine.medical_specialtyCirrhosisGenotypeCost-Benefit AnalysisHepacivirusDiseaseAntiviral AgentsGastroenterologyVirological response03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineRibavirinHumansMedicine030212 general & internal medicineStage (cooking)Adverse effectHepatologybusiness.industryHcv clearanceInterferon-alphaHepatitis CHepatitis C Chronicmedicine.diseaseTreatment OutcomeImmunologyHCVDisease ProgressionDrug Therapy Combination030211 gastroenterology & hepatologybusiness
researchProduct